[go: up one dir, main page]

BR0014137A - Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica - Google Patents

Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica

Info

Publication number
BR0014137A
BR0014137A BR0014137-2A BR0014137A BR0014137A BR 0014137 A BR0014137 A BR 0014137A BR 0014137 A BR0014137 A BR 0014137A BR 0014137 A BR0014137 A BR 0014137A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
hydrogen
kinase
optionally substituted
Prior art date
Application number
BR0014137-2A
Other languages
English (en)
Inventor
Andrew Austen Mortlock
Nicholas John Keen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0014137A publication Critical patent/BR0014137A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, MéTODO PARA INIBIR A AURORA 2 QUINASE EM UM ANIMAL DE SANGUE QUENTE, USO DE UM COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Um composto da fórmula (I) ou um sal, éster, amida ou um pró-medicamento destes; onde e é O, ou S, S(O), S(O)~ 2~ ou NR^ 6^ onde R^ 6^ é hidrogênio de alquila C~ 1-6~; R^ 5^ é um anel aromático de 6 membros opcionalmente substituído contendo pelo menos um átomo de nitrogênio e R^ 1^, R^ 2^, R^ 3^, R^ 4^ são independentemente selecionados de halogênio, ciano, nitro, alquila C~ 1-3~ sulfanila, -N(OH)R^ 7^- (em que R^ 7^ é hidrogênio, ou alquila C~ 1-3~), ou R^ 9^X^ 1^-(em que X^ 1^ representa uma ligação direta -O-, -CH~ 2~-, -OC(O), -C(O)-, -S-, -SO-, -SO~ 2~-, -NR^ 10^C(O)-, -C(O)NR^ 11^-, -SO~ 2~NR^ 12^-, -NR^ 13^ SO~ 2~- ou NR^ 14^- (em que R^ 10^, R^ 11^, R^ 12^ e R^ 13^ cada um, representa independentemente hidrogênio, alquila C~ 1-3~ ou alcóxi C~ 1-3~ alquila C~ 2-3~), e R^ 9^ é hidrogênio, hidrocarbila opcionalmente substituída, heterociclila opcionalmente substituída ou alcóxi opcionalmente substituído; contanto que pelo menos um de R^ 2^ ou R^ 3^ seja outro que não hidrogênio. Estes compostos inibem a aurora 2 quinase e são úteis na preparação de medicamentos para o tratamento de doenças proliferativas, tais como o câncer.
BR0014137-2A 1999-09-21 2000-09-19 Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica BR0014137A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003593 WO2001021597A1 (en) 1999-09-21 2000-09-19 Therapeutic quinazoline derivatives

Publications (1)

Publication Number Publication Date
BR0014137A true BR0014137A (pt) 2002-05-21

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014137-2A BR0014137A (pt) 1999-09-21 2000-09-19 Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica

Country Status (24)

Country Link
US (1) US7235559B1 (pt)
EP (1) EP1218355A1 (pt)
JP (1) JP2003509500A (pt)
KR (1) KR20020030123A (pt)
CN (1) CN1391563A (pt)
AR (1) AR025735A1 (pt)
AU (1) AU762697B2 (pt)
BG (1) BG106526A (pt)
BR (1) BR0014137A (pt)
CA (1) CA2384296A1 (pt)
CO (1) CO5200783A1 (pt)
CZ (1) CZ20021008A3 (pt)
EE (1) EE200200118A (pt)
GB (1) GB9922171D0 (pt)
HK (1) HK1046685A1 (pt)
HU (1) HUP0300205A3 (pt)
IL (1) IL148496A0 (pt)
IS (1) IS6310A (pt)
NO (1) NO20021400L (pt)
PL (1) PL354870A1 (pt)
SK (1) SK3872002A3 (pt)
TR (1) TR200200717T2 (pt)
WO (1) WO2001021597A1 (pt)
ZA (1) ZA200202232B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133897D1 (de) * 2000-06-28 2008-06-19 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
JP2002293773A (ja) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd キナゾリン誘導体の製造方法
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
KR20040085151A (ko) 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7560558B2 (en) * 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
MXPA05004858A (es) 2002-11-04 2005-07-22 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina de src.
DE60331479D1 (de) 2002-12-20 2010-04-08 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003290279A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
CN1753889A (zh) 2002-12-24 2006-03-29 阿斯利康(瑞典)有限公司 喹唑啉化合物
ATE412657T1 (de) * 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
DE60328735D1 (de) 2002-12-24 2009-09-17 Astrazeneca Ab Chinazolinderivate
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
JP2006526599A (ja) * 2003-06-02 2006-11-24 アストラゼネカ アクチボラグ 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての（３−（（キナゾリン−４−イル）アミノ）−１ｈ−ピラゾール−１−イル）アセトアミド誘導体及び関連化合物
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
CN102432552B (zh) * 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
CA2540342A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005075439A1 (en) 2004-02-03 2005-08-18 Astrazeneca Ab Quinazoline derivatives
RU2006139258A (ru) 2004-04-08 2008-05-20 Таргеджен, Инк. (US) Бензотриазиновые ингибиторы киназ
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
JP4237242B2 (ja) 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
ES2319462T3 (es) * 2005-03-28 2009-05-07 Bristol-Myers Squibb Company Inhibidores competitivos de atp cinasas.
WO2006108489A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
MY150290A (en) 2008-02-07 2013-12-31 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
CN110818633A (zh) 2009-01-16 2020-02-21 埃克塞里艾克西斯公司 一种苹果酸盐及其晶型
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
SI3046584T1 (sl) 2013-09-16 2017-10-30 Astrazeneca Ab Terapevtski polimerni nanodelci in postopek njihove izdelave in uporabe
JP6474166B2 (ja) 2014-01-01 2019-02-27 メディベイション テクノロジーズ エルエルシー 化合物及び使用方法
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
HRP20220648T1 (hr) 2017-08-07 2022-09-02 Alkermes, Inc. Biciklički inhibitori histonske deacetilaze
EP4006036A4 (en) * 2019-08-20 2022-09-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TETRACYCLIC COMPOUND USED AS A CDC7 INHIBITOR
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2366998A1 (en) * 1999-03-19 2000-09-28 Mingshu Li Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
EP1218355A1 (en) 2002-07-03
NO20021400L (no) 2002-05-06
IS6310A (is) 2002-03-19
JP2003509500A (ja) 2003-03-11
WO2001021597A1 (en) 2001-03-29
CO5200783A1 (es) 2002-09-27
CN1391563A (zh) 2003-01-15
SK3872002A3 (en) 2002-12-03
IL148496A0 (en) 2002-09-12
KR20020030123A (ko) 2002-04-22
BG106526A (en) 2002-10-31
AU7301900A (en) 2001-04-24
TR200200717T2 (tr) 2002-06-21
HUP0300205A3 (en) 2003-08-28
PL354870A1 (en) 2004-03-08
US7235559B1 (en) 2007-06-26
NO20021400D0 (no) 2002-03-20
ZA200202232B (en) 2003-08-27
AU762697B2 (en) 2003-07-03
CZ20021008A3 (cs) 2002-06-12
HUP0300205A2 (en) 2003-05-28
EE200200118A (et) 2003-04-15
HK1046685A1 (zh) 2003-01-24
GB9922171D0 (en) 1999-11-17
AR025735A1 (es) 2002-12-11
CA2384296A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
PT652868E (pt) Inibidores da fosfodiesterase do amp ciclico
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
DK452682A (da) Hidtil ukendte imidazolderivater, fremgangsmaade til deres fremstilling og farmaceutiske praeparater indeholdende dem
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
DE3681359D1 (de) 6-phenyl-pyridazin-verbindungen.
BRPI0413384A (pt) inibidores da proteìna farnesil transferase como agentes antitumores
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
KR940009184A (ko) 피라졸 축합환 유도체, 이의 제조방법 및 안드로겐 억제제
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
HUP9700810A2 (hu) Diozmetinsavak és -észterek, és a vegyületeket tartalmazó gyógyszerkészítmények
DE69217613D1 (de) Stickstoff enthaltende bizyklische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
HUP9903526A2 (hu) Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.